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Introduction
Since 2005, Burkina Faso adopted artesunate plus amodia-
quine (ASAQ) and artemether-lumefantrine (AL) as first-
line treatment for uncomplicated malaria. Despite
improvement in that treatment, malaria remains the first
cause of morbidity and mortality in the country.
Objectives
This study aimed to analyze the therapeutic efficacies of
ASAQ and AL for the treatment of uncomplicated falci-
parum malaria in Burkina Faso five years after their
adoption.
Methods
Per-protocol individual data from four randomized clinical
trials supported by IRSS-DRO Bobo Dioulasso in 2006,
2008, 2009 and 2010, including 1076 patients with uncom-
plicated P. falciparum malaria, treated with the reco-
mmended regimen of AL or ASAQ, were analyzed
according to WWARN analytical methods. Patients bene-
fited from a clinical and biological 28-day follow-up and
performed on days 2, 3, 7, 14 and 28 to evaluate clinical
and parasitological outcomes. Treatment failures have
been corrected by PCR.
Results
Using WWARN analytical methods, the unadjusted
Kaplan-Meier survival estimates are 76.4% (95% CI
(72.5-79.8)) in the AL group (N=544) and 87.1% (95% CI
(83.9-89.7)) in the ASAQ group (N=532). After PCR
correction, AL was less efficacious than ASAQ respectively
95.8% (95% CI (93.6-97.3)) vs 98.2% (95% CI (96.6-99.1));
OR=0,486 (95% CI (0.217-1.089). There was no significant
correlation between the occurrence of recrudescent at day
28 end-point and study year in two groups (coefficient<0).
Conclusion
AL and ASAQ remain effective as treatment for uncom-
plicated malaria according to WHO recommendations,
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